Receptor Drug Reduces Memory Loss, Oxidative Stress in Alzheimer’s Disease
Research presented at the 14th International Conference on Endothelin: Physiology, Pathophysiology and Therapeutics discussed a chemical that binds to endothelin B receptors used to treat Alzheimer’s disease in rats, which may be able to halt the disease from progressing. Using endothelin B receptors via intravenous injection of IRL-1620 (a chemical that binds to endothelin B receptors) to attempt to prevent and repair the damage to the brain caused by Alzheimer’s disease, researchers found that treatment with IRL-1620 reversed some effects. “Intravenous injection with the drug improved memory deficit by 50 to 60 percent and reduced oxidative stress by 45 to 50 percent,” one of the study’s co-authors explained. “We also found that treatment with IRL-1620 enhanced certain recovery processes within the AD-damaged brain, resulting in more new blood vessels and neuronal cells. This indicates reparative processes occurring in the damaged brain.” To read more about this study, click here.
Winter Clinics for Cranial and Spinal Surgery
Feb. 25, 2018 - Mar. 1, 2018; Snowmass Village, Colo.
69th Southern Neurosurgical Society Annual Meeting
Feb. 28, 2018 - Mar. 3, 2018; San Juan, PR
Second International Brain Mapping Course
April 26-27, 2018; New Orleans
2018 AANS Annual Scientific Meeting
April 28-May 2, 2018; New Orleans
2018 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting
Jun. 2, 2018 - Jun. 5, 2018; Denver